Jubilant Pharmova Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 15,332.2 million compared to INR 12,976 million a year ago. Revenue was INR 1,519.8 million compared to INR 13,164.4 million a year ago. Net loss was INR 156.7 million compared to net income of INR 509.9 million a year ago. Basic loss per share from continuing operations was INR 0.98 compared to basic earnings per share from continuing operations of INR 3.2 a year ago. Diluted loss per share from continuing operations was INR 0.98 compared to diluted earnings per share from continuing operations of INR 3.2 a year ago.
For the nine months, sales was INR 45,584.3 million compared to INR 45,447.3 million a year ago. Revenue was INR 46,376.1 million compared to INR 46,168.8 million a year ago. Net income was INR 368.6 million compared to INR 3,543.9 million a year ago. Basic earnings per share from continuing operations was INR 2.32 compared to INR 22.26 a year ago. Diluted earnings per share from continuing operations was INR 2.32 compared to INR 22.26 a year ago.